Development Insights 2021
Development Insights 2021
  • Home
  • About Us
  • Services
  • Industry Highlights
  • Careers
  • Contact Us
  • Inside DI
  • More
    • Home
    • About Us
    • Services
    • Industry Highlights
    • Careers
    • Contact Us
    • Inside DI
  • Sign In
  • Create Account

  • My Account
  • Signed in as:

  • filler@godaddy.com


  • My Account
  • Sign out

Signed in as:

filler@godaddy.com

  • Home
  • About Us
  • Services
  • Industry Highlights
  • Careers
  • Contact Us
  • Inside DI

Account


  • My Account
  • Sign out


  • Sign In
  • My Account

Products and Advances from Across the Industry

April 27, 2021

There is a public review being conducted starting today by FDA’s Oncologic Drugs Advisory Committee (ODAC) of six separate indications granted under the agency’s accelerated approval process that later failed to meet key endpoints in confirmatory clinical studies. The hearings involve 2 specific indications for atezolizumab (Tecentriq), 3 for pembrolizumab (Keytruda), and 1 for nivolumab (Opdivo), and based on the testimony, ODAC will consider whether the approvals should be withdrawn and/or whether additional trials should be conducted. Accelerated approval pathways have been important in oncology drug development, with oncology indications accounting for 85% of drugs approved through this pathway. It will be interesting to see how these hearings begin to shape future accelerated approvals, as many of these approvals have also provided significant benefits to critically ill patients.


Read more here

January 26, 2021

Interesting article about a CRISPR-based lineage tracing technique that can be used to predict the behavior of cancer cells and identification of tumor spreading patterns associated with disease progression. By identifying genes that contribute to this metastatic activity, more selective and targeted therapies can be developed to inhibit the spread of disease. 


Read more here

August 24, 2020

Exciting news in the treatment of glioblastoma! Improved survival, calculated at 17.7 months, compared to 12.7 months for standard of care. FDA has granted Fast Track Designation to paxalisib (formerly GDC-0084) from Australian-based Kazia Therapeutics Limited for the treatment of glioblastoma, the most common and aggressive form of primary brain cancer.


Read more here

Copyright © 2023 Development Insights - All Rights Reserved.

Powered by GoDaddy

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. Google Analytics cookies help us improve our website by collecting and reporting information on how you use it. The cookies collect information in a way that does not directly identify anyone. If you continue without changing your settings, we will assume that you consent to receive cookies from this website. You can change your cookie settings at any time. 

CONTINUE